Health Care & Life Sciences » Pharmaceuticals | Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
57.89 M
Public Float
-
Jazz Pharmaceuticals PLC
Stock Exchange NASDAQ Stock Market
EPS
$8.02
Market Cap
$7.99 B
Shares Outstanding
56.64 M
Public Float
55.03 M

Profile

Address
Waterloo Exchange
Dublin Dublin 4
Ireland
Employees -
Website http://www.jazzpharma.com
Updated 07/08/2019
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C.

Financials

View All
Created with Highcharts 5.0.14Jazz Pharmaceuticals PLCNet Income. Fiscal year is January-December. All values USD Millions.21621658583303303973974884884474472013201420152016201720180100200300400500600
Created with Highcharts 5.0.14Jazz Pharmaceuticals PLCSales/Revenue. Fiscal year is January-December. All values USD Millions.8728721 1731 1731 3251 3251 4881 4881 6191 6191 8911 8912013201420152016201720180500100015002000

Bruce C. Cozadd
Chairman & Chief Executive Officer
Peter Gray
Non-Executive Director